NCT04352335 is a clinical trial in Advanced Lung Cancer, sponsored by Chung Shan Medical University.

Who is sponsoring NCT04352335?

NCT04352335 is sponsored by Chung Shan Medical University.

What condition does NCT04352335 study?

NCT04352335 studies Advanced Lung Cancer.

Is NCT04352335 still recruiting?

NCT04352335 is currently completed. Last updated 2 July 2020.

Last reviewed 2020-07-02 · How we verify

NCT04352335

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator

Completed Last updated 2 July 2020

What this trial tests

trial in Advanced Lung Cancer in 53 participants. Completed in 1 July 2020.

Timeline

14 April 2020

Primary endpoint
1 July 2020

1 July 2020

Quick facts

Lead sponsor	Chung Shan Medical University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	53
Start date	14 April 2020
Primary completion	1 July 2020
Estimated completion	1 July 2020
Sites	1 location across Taiwan

Conditions studied

Advanced Lung Cancer — all drugs for Advanced Lung Cancer →

Sponsor

Chung Shan Medical University

Who can join

20 and older, any sex, with Advanced Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of post-treatment NLR and overall survival in advanced lung cancer patients by retrospective review.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Astragalus Polysaccharide Injection (PG2) Normalizes the Neutrophil-to-Lymphocyte Ratio in Patients with Advanced Lung Cancer Receiving Immunotherapy.
Tsao SM, Wu TC, Chen J, Chang F, et al · · 2021 · cited 34× · PMID 33583212 · DOI 10.1177/1534735421995256
Harnessing myeloid cells in cancer.
Park SY, Pylaeva E, Bhuria V, Gambardella AR, et al · · 2025 · cited 15× · PMID 40050933 · DOI 10.1186/s12943-025-02249-2
Immune checkpoint blockade in cancer: current insights and future horizons.
Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, et al · · 2026 · PMID 41483376 · DOI 10.1007/s12672-025-04361-7

Verify or expand the search:

Other recruiting trials for Advanced Lung Cancer

Currently open trials in the same condition.

NCT07227623 — A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors · NA · recruiting
NCT06992583 — Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer · Phase 1 · recruiting
NCT06945523 — Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advan · Phase 1 · recruiting
NCT06903117 — Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma · Phase 1 · recruiting
NCT06928922 — Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors. · EARLY_PHASE1 · recruiting

Other Chung Shan Medical University trials

Trials by the same sponsor.

NCT07443540 — The Effect of Acupuncture on Pulmonary Function Recovery Following Lung Resection · NA · not yet recruiting
NCT07504029 — Human Clinical Trial Evaluating the Blood Glucose-Regulating Effects of Momordica Charantia Peptides · NA · recruiting
NCT07252557 — Mouthwash Temperature and Oral Mucositis in Head and Neck Radiotherapy · NA · not yet recruiting
NCT07282496 — Evaluation of VEDAN RT-90 Resistant Cassava Starch for Glycemic Control and Prebiotic Fiber Development in a Human Trial · NA · not yet recruiting
NCT07504016 — Development of a Novel Cookie Formulation and Evaluation of Its Effects on Glycemic Control in Healthy Individuals · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04352335 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chung Shan Medical University
Last refreshed: 2 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04352335.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing